The full trial showed numerical trends but no statistical significance, while pre-specified subgroup analyses (about 78% of patients) showed significant improvements and safety like placebo; these results require a confirmatory study, so they do not change the company outlook.
BioVie reported Phase 2 topline results where the full intent-to-treat group showed trends but no statistical significance, while pre-specified subgroups (about 78%) showed significant benefit; the data is mixed and needs a confirmatory study.
Follow BioVie Inc. (BIVI) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for BIVI